Q-omics provides the consensus-scored NSUN5 profile across patient tissues and cancer cell-line models. NSUN5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NSUN5 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, NSUN5 protein abundance shows 31,134 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, COAD, and LUAD as cancer lineages where NSUN5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NSUN5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NSUN5 survival associations across molecular data types. NSUN5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NSUN5 RNA expression–survival associations across cancer types. High NSUN5 expression shows unfavorable associations in KIRC, ACC, KICH, LIHC, COAD and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NSUN5 RNA expression.
This table summarizes NSUN5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 10. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NSUN5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NSUN5 shows higher tumor expression in COAD, KIRP, LUAD, HNSC, LIHC and STAD. The COAD box plot shows higher NSUN5 RNA expression in tumor versus normal tissue (log2 FC = +1.430, t-test p < 0.001).
This table shows molecular features associated with NSUN5 in patient tissues and cancer cell lines. In patient samples, NSUN5 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NSUN5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
